Prelude Therapeutics stock gains as FDA clears new breast cancer drug trial
Published on 09/20/2026 at 21:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Prelude Therapeutics stock (ISIN US74065L1089) closed at 4.87 USD on Nasdaq on September 18, 2026, marking a 6.56 percent gain for that trading day and a 67.9 percent rise year to date from 2.90 USD at the start of 2026. As of that close, the shares were trading between a 52-week low of 0.98 USD and a 52-week high of 6.83 USD, giving investors a sense of the volatility in this early-stage oncology name.
FDA clearance for PRT13722 drives sentiment
A key recent catalyst for Prelude Therapeutics stock has been regulatory progress for one of its pipeline assets. According to MarketBeat, Prelude Therapeutics has received U.S. Food and Drug Administration clearance of an Investigational New Drug (IND) application for PRT13722, described as a first-in-class oral KAT6A inhibitor being developed for hormone receptor-positive, HER2-negative breast cancer. This clearance allows the company to initiate a Phase 1 clinical trial in patients, a step that investors often view as critical for value creation in early-stage biotechnology.
The same overview notes that Prelude Therapeutics stock was trading at 2.90 USD at the start of 2026 and has since risen to 4.87 USD as of the September 18, 2026 close, an increase of 67.9 percent over that period. This quantified move underlines how regulatory milestones such as the PRT13722 IND clearance have contributed to renewed market interest in the shares over the course of the year.
Pipeline breadth and analyst stance
Beyond PRT13722, Prelude Therapeutics is working on a broader pipeline of small-molecule targeted cancer therapies. As summarized by MarketBeat, the company is active in the biotechnology segment of the healthcare sector and has attracted multiple analyst views, with the stock characterized as having an average recommendation of Hold. While the detailed ratings and price targets are not broken out in the available snippet, this Hold stance reflects a balance between optimism about the oncology pipeline and caution over execution risks typical for clinical-stage companies.
The PRT13722 program itself targets KAT6A, an epigenetic regulator implicated in cancer cell growth. First-in-class status means Prelude Therapeutics is pursuing a mechanism not yet validated in the clinic, which can support upside if early data are positive but also increases uncertainty. For investors, the start of a Phase 1 study following IND clearance is usually the point at which safety and initial signals of activity begin to emerge, making subsequent readouts an important risk factor for the stock.
Stock performance and trading context
From a trading perspective, Prelude Therapeutics stock shows a relatively wide 52-week range between 0.98 USD and 6.83 USD per share, as indicated by the Nasdaq quote data compiled by MarketBeat. With the September 18, 2026 closing price at 4.87 USD, the shares are trading meaningfully above the 52-week low but still below the 52-week high, which highlights both the recovery from earlier weakness and the remaining headroom if future clinical and regulatory updates are favorable.
MarketBeat also reports that Prelude Therapeutics shares gained 0.30 USD, or 6.56 percent, on September 18, 2026, moving within an intraday range of 4.51 USD to 4.87 USD. For investors tracking liquidity and volatility, such single-day percentage moves are not unusual for small-cap biotechnology stocks, where news flow, sentiment toward the broader sector and changes in risk appetite can translate into rapid price shifts.
Closing price and investor takeaway
As of the Nasdaq closing auction on September 18, 2026, Prelude Therapeutics stock stood at 4.87 USD per share, with an extended-hours indication of 4.95 USD later that day according to data cited by MarketBeat. The year-to-date gain of 67.9 percent from 2.90 USD, combined with the 52-week range from 0.98 USD to 6.83 USD, underscores how closely investors are tying the valuation to clinical progress such as the FDA IND clearance for PRT13722 and the advancement of the company's broader oncology pipeline.
Prelude Therapeutics stock key data
- Company: Prelude Therapeutics Incorporated
- ISIN: US74065L1089
- Ticker: PRLD
- Trading venue: Nasdaq
- Price (as of September 18, 2026, 04:00 PM): 4.87 USD
- Market capitalization: [value not stated in available sources] USD (as of September 18, 2026)
- Sector / Industry: Healthcare / Biotechnology
- Index membership: Nasdaq composite-related
